Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention and Treatment of Osteoporotic Refracture
NCT05866029Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2023
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of teriparatide in osteoporosis, sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence of new vertebral fractures at 24 months. Started May 2023; status: recruiting.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05866029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866029.